Statins and Cardiomyocyte Metabolism, Friend or Foe?
Abstract
:1. Introduction
2. Cholesterol Synthesis and Beyond
3. Statins Beneficially Affect the Diseased Heart
4. Undesired Effects of Statins on Cardiomyocytes
5. Mitohormesis 2.0: Explaining the Difference between Statin Adverse Effects on Skeletal and Cardiac Myocytes
6. Outlook
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Ridker, P.M.; Danielson, E.; Fonseca, F.A.H.; Genest, J.; Gotto, A.M.; Kastelein, J.J.P.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008, 359, 2195–2207. [Google Scholar] [CrossRef] [PubMed]
- Rogers, J.K.; Jhund, P.S.; Perez, A.C.; Bohm, M.; Cleland, J.G.; Gullestad, L.; Kjekshus, J.; van Veldhuisen, D.J.; Wikstrand, J.; Wedel, H.; et al. Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014, 2, 289–297. [Google Scholar] [CrossRef]
- Yoshimura, S.; Uchida, K.; Daimon, T.; Takashima, R.; Kimura, K.; Morimoto, T.; Tanada, S.; Iida, T.; Kuroda, J.; Nose, A.; et al. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke. Stroke 2017, 48, 3057–3063. [Google Scholar] [CrossRef] [PubMed]
- Pisaniello, A.D.; Scherer, D.J.; Kataoka, Y.; Nicholls, S.J. Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opin. Pharmacother. 2015, 16, 347–356. [Google Scholar] [CrossRef]
- Hennessy, E.; Adams, C.; Reen, F.J.; O’Gara, F. Is There Potential for Repurposing Statins as Novel Antimicrobials? Antimicrob. Agents Chemother. 2016, 60, 5111–5121. [Google Scholar] [CrossRef]
- Cholesterol Treatment Trialists’, C.; Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376, 1670–1681. [Google Scholar] [CrossRef] [PubMed]
- Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366, 1267–1278. [Google Scholar] [CrossRef] [PubMed]
- Kearney, P.M.; Blackwell, L.; Collins, R.; Keech, A.; Simes, J.; Peto, R.; Armitage, J.; Baigent, C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008, 371, 117–125. [Google Scholar] [CrossRef]
- Sever, P.S.; Dahlof, B.; Poulter, N.R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm: A multicentre randomised trial. Lancet 2003, 361, 1149. [Google Scholar] [CrossRef]
- Cholesterol Treatment Trialists, C.; Mihaylova, B.; Emberson, J.; Blackwell, L.; Keech, A.; Simes, J.; Barnes, E.H.; Voysey, M.; Gray, A.; Collins, R.; et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380, 581–590. [Google Scholar] [CrossRef]
- Buettner, C.; Davis, R.B.; Leveille, S.G.; Mittleman, M.A.; Mukamal, K.J. Prevalence of Musculoskeletal Pain and Statin Use. J. Gen. Intern. Med. 2008, 23, 1182–1186. [Google Scholar] [CrossRef]
- Armitage, J. The safety of statins in clinical practice. Lancet 2007, 370, 1781–1790. [Google Scholar] [CrossRef] [PubMed]
- Stroes, E.S.; Thompson, P.D.; Corsini, A.; Vladutiu, G.D.; Raal, F.J.; Ray, K.K.; Roden, M.; Stein, E.; Tokgözoğlu, L.; Nordestgaard, B.G.; et al. Statin-associated muscle symptoms: Impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 2015, 36, 1012–1022. [Google Scholar] [CrossRef] [PubMed]
- Hoffman, K.B.; Kraus, C.; Dimbil, M.; Golomb, B.A. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS ONE 2012, 7, e42866. [Google Scholar] [CrossRef]
- Gupta, A.; Thompson, D.; Whitehouse, A.; Collier, T.; Dahlof, B.; Poulter, N.; Collins, R.; Sever, P. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017, 389, 2473–2481. [Google Scholar] [CrossRef] [PubMed]
- Vonbank, A.; Drexel, H.; Agewall, S.; Lewis, B.S.; Dopheide, J.F.; Kjeldsen, K.; Ceconi, C.; Savarese, G.; Rosano, G.; Wassmann, S.; et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: A review. Eur. Heart J.-Cardiovasc. Pharmacother. 2018, 4, 230–236. [Google Scholar] [CrossRef]
- Rosenson, R.S.; Baker, S.; Banach, M.; Borow, K.M.; Braun, L.T.; Bruckert, E.; Brunham, L.R.; Catapano, A.L.; Elam, M.B.; Mancini, G.B.J.; et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J. Am. Coll. Cardiol. 2017, 70, 1290–1301. [Google Scholar] [CrossRef]
- Nikolic, D.; Banach, M.; Chianetta, R.; Luzzu, L.M.; Pantea Stoian, A.; Diaconu, C.C.; Citarrella, R.; Montalto, G.; Rizzo, M. An overview of statin-induced myopathy and perspectives for the future. Expert Opin. Drug Saf. 2020, 19, 601–615. [Google Scholar] [CrossRef]
- Schirris, T.J.J.; Renkema, G.H.; Ritschel, T.; Voermans, N.C.; Bilos, A.; van Engelen, B.G.M.; Brandt, U.; Koopman, W.J.H.; Beyrath, J.D.; Rodenburg, R.J.; et al. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metab. 2015, 22, 399–407. [Google Scholar] [CrossRef] [PubMed]
- Prueksaritanont, T.; Subramanian, R.; Fang, X.; Ma, B.; Qiu, Y.; Lin, J.H.; Pearson, P.G.; Baillie, T.A. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab. Dispos. 2002, 30, 505–512. [Google Scholar] [CrossRef]
- Schirris, T.J.; Ritschel, T.; Bilos, A.; Smeitink, J.A.; Russel, F.G. Statin Lactonization by Uridine 5’-Diphospho-glucuronosyltransferases (UGTs). Mol. Pharm. 2015, 12, 4048–4055. [Google Scholar] [CrossRef]
- Riedmaier, S.; Klein, K.; Hofmann, U.; Keskitalo, J.E.; Neuvonen, P.J.; Schwab, M.; Niemi, M.; Zanger, U.M. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin. Pharmacol. Ther. 2010, 87, 65–73. [Google Scholar] [CrossRef]
- Allard, N.A.E.; Schirris, T.J.J.; Verheggen, R.J.; Russel, F.G.M.; Rodenburg, R.J.; Smeitink, J.A.M.; Thompson, P.D.; Hopman, M.T.E.; Timmers, S. Statins Affect Skeletal Muscle Performance: Evidence for Disturbances in Energy Metabolism. J. Clin. Endocrinol. Metab. 2017, 103, 75–84. [Google Scholar] [CrossRef]
- Godoy, J.C.; Niesman, I.R.; Busija, A.R.; Kassan, A.; Schilling, J.M.; Schwarz, A.; Alvarez, E.A.; Dalton, N.D.; Drummond, J.C.; Roth, D.M.; et al. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J. 2019, 33, 1209–1225. [Google Scholar] [CrossRef]
- Bell, R.M.; Yellon, D.M. Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. 2003, 41, 508–515. [Google Scholar] [CrossRef] [PubMed]
- Bouitbir, J.; Charles, A.-L.; Echaniz-Laguna, A.; Kindo, M.; Daussin, F.; Auwerx, J.; Piquard, F.; Geny, B.; Zoll, J. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: A ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur. Heart J. 2012, 33, 1397–1407. [Google Scholar] [CrossRef] [PubMed]
- Cianflone, E.; Cappetta, D.; Mancuso, T.; Sabatino, J.; Marino, F.; Scalise, M.; Albanese, M.; Salatino, A.; Parrotta, E.I.; Cuda, G.; et al. Statins Stimulate New Myocyte Formation After Myocardial Infarction by Activating Growth and Differentiation of the Endogenous Cardiac Stem Cells. Int. J. Mol. Sci. 2020, 21, 7927. [Google Scholar] [CrossRef] [PubMed]
- Hayashidani, S.; Tsutsui, H.; Shiomi, T.; Suematsu, N.; Kinugawa, S.; Ide, T.; Wen, J.; Takeshita, A. Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction. Circulation 2002, 105, 868–873. [Google Scholar] [CrossRef]
- Jones Steven, P.; Teshima, Y.; Akao, M.; Marbán, E. Simvastatin Attenuates Oxidant-Induced Mitochondrial Dysfunction in Cardiac Myocytes. Circ. Res. 2003, 93, 697–699. [Google Scholar] [CrossRef]
- Cerqueira, N.M.F.S.A.; Oliveira, E.F.; Gesto, D.S.; Santos-Martins, D.; Moreira, C.; Moorthy, H.N.; Ramos, M.J.; Fernandes, P.A. Cholesterol Biosynthesis: A Mechanistic Overview. Biochemistry 2016, 55, 5483–5506. [Google Scholar] [CrossRef]
- Miziorko, H.M. Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch. Biochem. Biophys. 2011, 505, 131–143. [Google Scholar] [CrossRef] [PubMed]
- Waterham, H.R. Defects of cholesterol biosynthesis. FEBS Lett. 2006, 580, 5442–5449. [Google Scholar] [CrossRef]
- Goldstein, J.L.; Brown, M.S. Regulation of the mevalonate pathway. Nature 1990, 343, 425–430. [Google Scholar] [CrossRef]
- Stancu, C.; Sima, A. Statins: Mechanism of action and effects. J. Cell. Mol. Med. 2001, 5, 378–387. [Google Scholar] [CrossRef] [PubMed]
- Ginsberg, H.N.; Le, N.A.; Short, M.P.; Ramakrishnan, R.; Desnick, R.J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J. Clin. Investig. 1987, 80, 1692–1697. [Google Scholar] [CrossRef]
- Oesterle, A.; Laufs, U.; Liao, J.K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ. Res. 2017, 120, 229–243. [Google Scholar] [CrossRef]
- Xu, H.; Shen, Y.; Liang, C.; Wang, H.; Huang, J.; Xue, P.; Luo, M. Inhibition of the mevalonate pathway improves myocardial fibrosis. Exp. Ther. Med. 2021, 21, 224. [Google Scholar] [CrossRef]
- Cheng, C.; Liu, X.B.; Bi, S.J.; Lu, Q.H.; Zhang, J. Inhibition of Rho-kinase is involved in the therapeutic effects of atorvastatin in heart ischemia/reperfusion. Exp. Ther. Med. 2020, 20, 3147–3153. [Google Scholar] [CrossRef] [PubMed]
- Ding, J.; Chen, Y.X.; Chen, Y.; Mou, Y.; Sun, X.T.; Dai, D.P.; Zhao, C.Z.; Yang, J.; Hu, S.J.; Guo, X. Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes. J. Cell. Mol. Med. 2020, 24, 8998–9011. [Google Scholar] [CrossRef] [PubMed]
- Emelyanova, L.; Sra, A.; Schmuck, E.G.; Raval, A.N.; Downey, F.X.; Jahangir, A.; Rizvi, F.; Ross, G.R. Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts. ESC Heart Fail. 2019, 6, 1027–1040. [Google Scholar] [CrossRef]
- Kuo, H.-F.; Hsieh, C.-C.; Wang, S.-C.; Chang, C.-Y.; Hung, C.-H.; Kuo, P.-L.; Liu, Y.-R.; Li, C.-Y.; Liu, P.-L. Simvastatin Attenuates Cardiac Fibrosis via Regulation of Cardiomyocyte-Derived Exosome Secretion. J. Clin. Med. 2019, 8, 794. [Google Scholar] [CrossRef]
- Ramasubbu, K.; Estep, J.; White, D.L.; Deswal, A.; Mann, D.L. Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy. J. Am. Coll. Cardiol. 2008, 51, 415–426. [Google Scholar] [CrossRef]
- Su, S.-F.; Hsiao, C.-L.; Chu, C.-W.; Lee, B.-C.; Lee, T.-M. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am. J. Cardiol. 2000, 86, 514–518. [Google Scholar] [CrossRef]
- Jain, M.K.; Ridker, P.M. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nat. Rev. Drug Discov. 2005, 4, 977–987. [Google Scholar] [CrossRef]
- Stumpf, C.; Petzi, S.; Seybold, K.; Wasmeier, G.; Arnold, M.; Raaz, D.; Yilmaz, A.; Daniel, W.G.; Garlichs, C.D. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin. Sci. 2009, 116, 45–52. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Cheng, X.; Liao, Y.-H.; Lu, B.; Yang, Y.; Li, B.; Ge, H.; Wang, M.; Liu, Y.; Guo, Z.; et al. Simvastatin Regulates Myocardial Cytokine Expression and Improves Ventricular Remodeling in Rats after Acute Myocardial Infarction. Cardiovasc. Drugs Ther. 2005, 19, 13–21. [Google Scholar] [CrossRef] [PubMed]
- Pentz, R.; Kaun, C.; Thaler, B.; Stojkovic, S.; Lenz, M.; Krychtiuk, K.A.; Zuckermann, A.; Huber, K.; Wojta, J.; Hohensinner, P.J.; et al. Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue. J. Cell. Mol. Med. 2018, 22, 6122–6133. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Chen, Z.; Guo, J.; Peng, X.; Zheng, Z.; Chen, H.; Liu, H.; Ma, Y. Atorvastatin-induced tolerogenic dendritic cells improve cardiac remodeling by suppressing TLR-4/NF-κB activation after myocardial infarction. Inflamm. Res. 2023, 72, 13–25. [Google Scholar] [CrossRef]
- Chen, A.; Chen, Z.; Zhou, Y.; Wu, Y.; Xia, Y.; Lu, D.; Fan, M.; Li, S.; Chen, J.; Sun, A.; et al. Rosuvastatin protects against coronary microembolization-induced cardiac injury via inhibiting NLRP3 inflammasome activation. Cell Death Dis. 2021, 12, 78. [Google Scholar] [CrossRef]
- Parsamanesh, N.; Karami-Zarandi, M.; Banach, M.; Penson, P.E.; Sahebkar, A. Effects of statins on myocarditis: A review of underlying molecular mechanisms. Prog. Cardiovasc. Dis. 2021, 67, 53–64. [Google Scholar] [CrossRef] [PubMed]
- Maack, C.; Kartes, T.; Kilter, H.; Schäfers, H.-J.; Nickenig, G.; Böhm, M.; Laufs, U. Oxygen Free Radical Release in Human Failing Myocardium Is Associated With Increased Activity of Rac1-GTPase and Represents a Target for Statin Treatment. Circulation 2003, 108, 1567–1574. [Google Scholar] [CrossRef]
- Kjekshus, J.; Pedersen, T.R.; Olsson, A.G.; Faergeman, O.; Pyörälä, K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail. 1997, 3, 249–254. [Google Scholar] [CrossRef]
- Belch, J.J.; Bridges, A.B.; Scott, N.; Chopra, M. Oxygen free radicals and congestive heart failure. Br. Heart J. 1991, 65, 245–248. [Google Scholar] [CrossRef] [PubMed]
- Mallat, Z.; Philip, I.; Lebret, M.; Chatel, D.; Maclouf, J.; Tedgui, A. Elevated Levels of 8-iso-Prostaglandin F2α in Pericardial Fluid of Patients With Heart Failure. Circulation 1998, 97, 1536–1539. [Google Scholar] [CrossRef] [PubMed]
- Node, K.; Fujita, M.; Kitakaze, M.; Hori, M.; Liao, J.K. Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy. Circulation 2003, 108, 839–843. [Google Scholar] [CrossRef] [PubMed]
- Tissier, F.; Farhat, F.; Philouze, C.; Desfontis, J.-C.; Didier, R.; Gilard, M.; Mallem, M.Y.; Mansourati, J.; Moisan, C.; Pichavant-Rafini, K.; et al. Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in Watanabe heritable hyperlipidemic rabbit. Can. J. Physiol. Pharmacol. 2018, 96, 1112–1118. [Google Scholar] [CrossRef]
- Ichihara, K.; Satoh, K.; Abiko, Y. Influences of Pravastatin and Simvastatin, HMG-CoA Reductase Inhibitors, on Myocardial Stunning in Dogs. J. Cardiovasc. Pharmacol. 1993, 22, 852–856. [Google Scholar] [CrossRef]
- Salerno, N.; Salerno, L.; Marino, F.; Scalise, M.; Chiefalo, A.; Panuccio, G.; De Angelis, A.; Cianflone, E.; Urbanek, K.; Torella, D. Myocardial regeneration protocols towards the routine clinical scenario: An unseemly path from bench to bedside. EClinicalMedicine 2022, 50, 101530. [Google Scholar] [CrossRef] [PubMed]
- Di Napoli, P.; Taccardi, A.A.; Grilli, A.; De Lutiis, M.A.; Barsotti, A.; Felaco, M.; De Caterina, R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia–reperfusion injury in rat hearts. Cardiovasc. Res. 2005, 66, 462–471. [Google Scholar] [CrossRef] [PubMed]
- Pasceri, V.; Patti, G.; Nusca, A.; Pristipino, C.; Richichi, G.; Sciascio, G.D. Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention. Circulation 2004, 110, 674–678. [Google Scholar] [CrossRef] [PubMed]
- Pan, W.; Pintar, T.; Anton, J.; Lee, V.V.; Vaughn, W.K.; Collard, C.D. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004, 110, II45–II49. [Google Scholar] [CrossRef]
- Eijsvogels, T.M.H.; Januzzi, J.L.; Taylor, B.A.; Isaacs, S.K.; D’Hemecourt, P.; Zaleski, A.; Dyer, S.; Troyanos, C.; Weiner, R.B.; Thompson, P.D.; et al. Impact of Statin Use on Exercise-Induced Cardiac Troponin Elevations. Am. J. Cardiol. 2014, 114, 624–628. [Google Scholar] [CrossRef]
- Li, H.; Wang, Y.; Liu, J.; Chen, X.; Duan, Y.; Wang, X.; Shen, Y.; Kuang, Y.; Zhuang, T.; Tomlinson, B.; et al. Endothelial Klf2-Foxp1-TGFβ signal mediates the inhibitory effects of simvastatin on maladaptive cardiac remodeling. Theranostics 2021, 11, 1609–1625. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Xu, Y.; Li, X.; Guo, Y.; Liu, G. Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: Role of TGF-β1–TAK1. Toxicol. Lett. 2012, 211, 91–97. [Google Scholar] [CrossRef]
- Liao, Y.; Zhao, H.; Ogai, A.; Kato, H.; Asakura, M.; Kim, J.; Asanuma, H.; Minamino, T.; Takashima, S.; Kitakaze, M. Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation. Hypertens. Res. 2008, 31, 335–344. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Liao, Y.; Minamino, T.; Asano, Y.; Asakura, M.; Kim, J.; Asanuma, H.; Takashima, S.; Hori, M.; Kitakaze, M. Inhibition of Cardiac Remodeling by Pravastatin Is Associated with Amelioration of Endoplasmic Reticulum Stress. Hypertens. Res. 2008, 31, 1977–1987. [Google Scholar] [CrossRef]
- Ozturk, N.; Uslu, S.; Mercan, T.; Erkan, O.; Ozdemir, S. Rosuvastatin Reduces L-Type Ca2+ Current and Alters Contractile Function in Cardiac Myocytes via Modulation of β-Adrenergic Receptor Signaling. Cardiovasc. Toxicol. 2021, 21, 422–431. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez-Sánchez, E.; Navarro-García, J.A.; González-Lafuente, L.; Aceves-Ripoll, J.; Vázquez-Sánchez, S.; Poveda, J.; Mercado-García, E.; Corbacho-Alonso, N.; Calvo-Bonacho, E.; Fernández-Velasco, M.; et al. Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes. Antioxidants 2020, 9, 1213. [Google Scholar] [CrossRef]
- Lee, Y.L.; Blaha, M.J.; Jones, S.R. Statin therapy in the prevention and treatment of atrial fibrillation. J. Clin. Lipidol. 2011, 5, 18–29. [Google Scholar] [CrossRef]
- Geiger, R.; Fatima, N.; Schooley, J.F., Jr.; Smyth, J.T.; Haigney, M.C.; Flagg, T.P. Novel cholesterol-dependent regulation of cardiac KATP subunit expression revealed using histone deacetylase inhibitors. Physiol. Rep. 2021, 8, e14675. [Google Scholar] [CrossRef] [PubMed]
- Rossello, X.; Yellon, D.M. The RISK pathway and beyond. Basic Res. Cardiol. 2017, 113, 2. [Google Scholar] [CrossRef]
- Vilahur, G.; Casaní, L.; Peña, E.; Duran, X.; Juan-Babot, O.; Badimon, L. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 2009, 206, 95–101. [Google Scholar] [CrossRef] [PubMed]
- Tsouli, S.G.; Liberopoulos, E.N.; Goudevenos, J.A.; Mikhailidis, D.P.; Elisaf, M.S. Should a statin be prescribed to every patient with heart failure? Heart Fail. Rev. 2008, 13, 211–225. [Google Scholar] [CrossRef] [PubMed]
- Tavazzi, L.; Maggioni, A.P.; Marchioli, R.; Barlera, S.; Franzosi, M.G.; Latini, R.; Lucci, D.; Nicolosi, G.L.; Porcu, M.; Tognoni, G.; et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 1231–1239. [Google Scholar] [CrossRef] [PubMed]
- Cannon, C.P.; Steinberg, B.A.; Murphy, S.A.; Mega, J.L.; Braunwald, E. Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. J. Am. Coll. Cardiol. 2006, 48, 438–445. [Google Scholar] [CrossRef]
- Mann, D.L.; McMurray, J.J.V.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; et al. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. Circulation 2004, 109, 1594–1602. [Google Scholar] [CrossRef]
- Sciarretta, S.; Forte, M.; Frati, G.; Sadoshima, J. New Insights Into the Role of mTOR Signaling in the Cardiovascular System. Circ. Res. 2018, 122, 489–505. [Google Scholar] [CrossRef]
- Groenewoud, M.J.; Zwartkruis, F.J.T. Rheb and mammalian target of rapamycin in mitochondrial homoeostasis. Open Biol. 2013, 3, 130185. [Google Scholar] [CrossRef] [PubMed]
- Irwin, J.C.; Fenning, A.S.; Vella, R.K. Statins with different lipophilic indices exert distinct effects on skeletal, cardiac and vascular smooth muscle. Life Sci. 2020, 242, 117225. [Google Scholar] [CrossRef] [PubMed]
- März, W.; Siekmeier, R.; Müller, H.-M.; Wieland, H.; Groß, W.; Olbrich, H.-G. Effects of Lovastatin and Pravastatin on the Survival of Hamsters With Inherited Cardiomyopathy. J. Cardiovasc. Pharmacol. Ther. 2000, 5, 275–279. [Google Scholar] [CrossRef]
- Ünlü, S.; Nurkoç, S.G.; Sezenöz, B.; Cingirt, M.; Gülbahar, Ö.; Abacı, A. Impact of statin use on high sensitive troponin T levels with moderate exercise. Acta Cardiol. 2019, 74, 380–385. [Google Scholar] [CrossRef] [PubMed]
- Okuyama, H.; Langsjoen, P.H.; Hamazaki, T.; Ogushi, Y.; Hama, R.; Kobayashi, T.; Uchino, H. Statins stimulate atherosclerosis and heart failure: Pharmacological mechanisms. Expert Rev. Clin. Pharmacol. 2015, 8, 189–199. [Google Scholar] [CrossRef]
- McMurray, J.J.; Dunselman, P.; Wedel, H.; Cleland, J.G.; Lindberg, M.; Hjalmarson, A.; Kjekshus, J.; Waagstein, F.; Apetrei, E.; Barrios, V.; et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: A pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J. Am. Coll. Cardiol. 2010, 56, 1196–1204. [Google Scholar] [CrossRef]
- Silver, M.A.; Langsjoen, P.H.; Szabo, S.; Patil, H.; Zelinger, A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am. J. Cardiol. 2004, 94, 1306–1310. [Google Scholar] [CrossRef] [PubMed]
- Langsjoen, P.H.; Langsjoen, J.O.; Langsjoen, A.M.; Lucas, L.A. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. BioFactors 2005, 25, 147–152. [Google Scholar] [CrossRef]
- Savarese, G.; Becher, P.M.; Lund, L.H.; Seferovic, P.; Rosano, G.M.C.; Coats, A.J.S. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc. Res. 2022, 118, 3272–3287. [Google Scholar] [CrossRef] [PubMed]
- Raizner, A.E.; Quiñones, M.A. Coenzyme Q10 for Patients With Cardiovascular Disease: JACC Focus Seminar. J. Am. Coll. Cardiol. 2021, 77, 609–619. [Google Scholar] [CrossRef]
- Moosmann, B.; Behl, C. Selenoprotein synthesis and side-effects of statins. Lancet 2004, 363, 892–894. [Google Scholar] [CrossRef]
- Attalla, D.M.; Ahmed, L.A.; Zaki, H.F.; Khattab, M.M. Paradoxical effects of atorvastatin in isoproterenol-induced cardiotoxicity in rats: Role of oxidative stress and inflammation. Biomed. Pharmacother. 2018, 104, 542–549. [Google Scholar] [CrossRef]
- Will, Y.; Shields, J.E.; Wallace, K.B. Drug-Induced Mitochondrial Toxicity in the Geriatric Population: Challenges and Future Directions. Biology 2019, 8, 32. [Google Scholar] [CrossRef]
- Bielecka-Dabrowa, A.; Fabis, J.; Mikhailidis, D.P.; von Haehling, S.; Sahebkar, A.; Rysz, J.; Banach, M. Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. Trends Pharmacol. Sci. 2018, 39, 331–353. [Google Scholar] [CrossRef]
- Cai, T.; Abel, L.; Langford, O.; Monaghan, G.; Aronson, J.K.; Stevens, R.J.; Lay-Flurrie, S.; Koshiaris, C.; McManus, R.J.; Hobbs, F.D.R.; et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: Systematic review with pairwise, network, and dose-response meta-analyses. BMJ 2021, 374, n1537. [Google Scholar] [CrossRef] [PubMed]
- Lotteau, S.; Ivarsson, N.; Yang, Z.; Restagno, D.; Colyer, J.; Hopkins, P.; Weightman, A.; Himori, K.; Yamada, T.; Bruton, J.; et al. A Mechanism for Statin-Induced Susceptibility to Myopathy. JACC Basic Transl. Sci. 2019, 4, 509–523. [Google Scholar] [CrossRef] [PubMed]
- Venturi, E.; Lindsay, C.; Lotteau, S.; Yang, Z.; Steer, E.; Witschas, K.; Wilson, A.D.; Wickens, J.R.; Russell, A.J.; Steele, D.; et al. Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform. Br. J. Pharmacol. 2018, 175, 938–952. [Google Scholar] [CrossRef]
- Lanner, J.T.; Georgiou, D.K.; Joshi, A.D.; Hamilton, S.L. Ryanodine receptors: Structure, expression, molecular details, and function in calcium release. Cold Spring Harb. Perspect. Biol. 2010, 2, a003996. [Google Scholar] [CrossRef]
- Gong, D.; Yan, N.; Ledford, H.A. Structural Basis for the Modulation of Ryanodine Receptors. Trends Biochem. Sci. 2021, 46, 489–501. [Google Scholar] [CrossRef] [PubMed]
- Boengler, K.; Kosiol, M.; Mayr, M.; Schulz, R.; Rohrbach, S. Mitochondria and ageing: Role in heart, skeletal muscle and adipose tissue. J. Cachexia Sarcopenia Muscle 2017, 8, 349–369. [Google Scholar] [CrossRef]
- Park, S.-Y.; Gifford, J.R.; Andtbacka, R.H.I.; Trinity, J.D.; Hyngstrom, J.R.; Garten, R.S.; Diakos, N.A.; Ives, S.J.; Dela, F.; Larsen, S.; et al. Cardiac, skeletal, and smooth muscle mitochondrial respiration: Are all mitochondria created equal? Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H346–H352. [Google Scholar] [CrossRef]
- Rocha, K.C.e.; Pereira, B.M.V.; Rodrigues, A.C. An update on efflux and uptake transporters as determinants of statin response. Expert Opin. Drug Metab. Toxicol. 2018, 14, 613–624. [Google Scholar] [CrossRef]
- Berglund, L.; Björling, E.; Oksvold, P.; Fagerberg, L.; Asplund, A.; Al-Khalili Szigyarto, C.; Persson, A.; Ottosson, J.; Wernérus, H.; Nilsson, P.; et al. A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies. Mol. Cell Proteom. 2008, 7, 2019–2027. [Google Scholar] [CrossRef]
- Skottheim, I.B.; Gedde-Dahl, A.; Hejazifar, S.; Hoel, K.; Åsberg, A. Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur. J. Pharm. Sci. 2008, 33, 317–325. [Google Scholar] [CrossRef] [PubMed]
- Matsushima, S.; Maeda, K.; Kondo, C.; Hirano, M.; Sasaki, M.; Suzuki, H.; Sugiyama, Y. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein. J. Pharmacol. Exp. Ther. 2005, 314, 1059–1067. [Google Scholar] [CrossRef] [PubMed]
- Fujino, H.; Saito, T.; Ogawa, S.-I.; Kojima, J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J. Pharm. Pharmacol. 2010, 57, 1305–1311. [Google Scholar] [CrossRef] [PubMed]
- Shmeeda, H.; Petkova, D.; Barenholz, Y. Cholesterol homeostasis in cultures of rat heart myocytes: Relationship to cellular hypertrophy. Am. J. Physiol.-Heart Circ. Physiol. 1994, 267, H1689–H1697. [Google Scholar] [CrossRef]
- Reboulleau, A.; Robert, V.; Vedie, B.; Doublet, A.; Grynberg, A.; Paul, J.-L.; Fournier, N. Involvement of cholesterol efflux pathway in the control of cardiomyocytes cholesterol homeostasis. J. Mol. Cell. Cardiol. 2012, 53, 196–205. [Google Scholar] [CrossRef]
- Yokoyama, M.; Seo, T.; Park, T.; Yagyu, H.; Hu, Y.; Son, N.H.; Augustus, A.S.; Vikramadithyan, R.K.; Ramakrishnan, R.; Pulawa, L.K.; et al. Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J. Lipid Res. 2007, 48, 646–655. [Google Scholar] [CrossRef]
- Laufs, U.; Kilter, H.; Konkol, C.; Wassmann, S.; Böhm, M.; Nickenig, G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc. Res. 2002, 53, 911–920. [Google Scholar] [CrossRef] [PubMed]
- Frambach, S.; de Haas, R.; Smeitink, J.A.M.; Rongen, G.A.; Russel, F.G.M.; Schirris, T.J.J. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. Pharmacol. Rev. 2020, 72, 152–190. [Google Scholar] [CrossRef]
- Kobayashi, M.; Otsuka, Y.; Itagaki, S.; Hirano, T.; Iseki, K. Inhibitory effects of statins on human monocarboxylate transporter 4. Int. J. Pharm. 2006, 317, 19–25. [Google Scholar] [CrossRef]
- Kostner, K.M. Statin therapy for hypertrophic cardiomyopathy: Too good to be true? Eur. J. Clin. Investig. 2010, 40, 965–967. [Google Scholar] [CrossRef]
- Marenzi, G.; Cosentino, N.; Cortinovis, S.; Milazzo, V.; Rubino, M.; Cabiati, A.; De Metrio, M.; Moltrasio, M.; Lauri, G.; Campodonico, J.; et al. Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Am. J. Cardiol. 2015, 116, 1791–1797. [Google Scholar] [CrossRef] [PubMed]
- Javaheri, A.; Rader, D.J.; Javaheri, S. Statin Therapy in Heart Failure. Hypertension 2014, 63, 909–910. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Somers, T.; Siddiqi, S.; Morshuis, W.J.; Russel, F.G.M.; Schirris, T.J.J. Statins and Cardiomyocyte Metabolism, Friend or Foe? J. Cardiovasc. Dev. Dis. 2023, 10, 417. https://doi.org/10.3390/jcdd10100417
Somers T, Siddiqi S, Morshuis WJ, Russel FGM, Schirris TJJ. Statins and Cardiomyocyte Metabolism, Friend or Foe? Journal of Cardiovascular Development and Disease. 2023; 10(10):417. https://doi.org/10.3390/jcdd10100417
Chicago/Turabian StyleSomers, Tim, Sailay Siddiqi, Wim J. Morshuis, Frans G. M. Russel, and Tom J. J. Schirris. 2023. "Statins and Cardiomyocyte Metabolism, Friend or Foe?" Journal of Cardiovascular Development and Disease 10, no. 10: 417. https://doi.org/10.3390/jcdd10100417